OBIO vs. BFLY, DCTH, TMCI, OM, CLPT, RXST, NPCE, SNWV, NNOX, and CATX
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Butterfly Network (BFLY), Delcath Systems (DCTH), Treace Medical Concepts (TMCI), Outset Medical (OM), ClearPoint Neuro (CLPT), RxSight (RXST), NeuroPace (NPCE), Sanuwave Health (SNWV), Nano-X Imaging (NNOX), and Perspective Therapeutics (CATX). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs. Its Competitors
Orchestra BioMed (NASDAQ:OBIO) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.
Orchestra BioMed currently has a consensus target price of $14.20, suggesting a potential upside of 347.95%. Butterfly Network has a consensus target price of $3.50, suggesting a potential upside of 87.67%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, research analysts clearly believe Orchestra BioMed is more favorable than Butterfly Network.
53.6% of Orchestra BioMed shares are held by institutional investors. Comparatively, 37.9% of Butterfly Network shares are held by institutional investors. 8.1% of Orchestra BioMed shares are held by company insiders. Comparatively, 25.2% of Butterfly Network shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Orchestra BioMed has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500.
Orchestra BioMed has higher earnings, but lower revenue than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Butterfly Network has a net margin of -75.56% compared to Orchestra BioMed's net margin of -2,297.85%. Butterfly Network's return on equity of -29.97% beat Orchestra BioMed's return on equity.
In the previous week, Butterfly Network had 2 more articles in the media than Orchestra BioMed. MarketBeat recorded 4 mentions for Butterfly Network and 2 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.85 beat Butterfly Network's score of 0.50 indicating that Orchestra BioMed is being referred to more favorably in the media.
Summary
Orchestra BioMed beats Butterfly Network on 9 of the 17 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 7/18/2025 by MarketBeat.com Staff
Free OBIO Stock Alerts